OBJECTIVES: Studies indicate that poor adherence and low persistence to treatment could lead in not achieving recommended glycemic goals in T2DM patients. The aim of this study was to assess the adherence and persistence of patients who initiate treatment with insulin or with glucagon-like peptides analogs (GLP-1) in Spain. METHODS: Observational, retrospective study based (funded by GSK) on review of medical records from patients located in Badalona sanitary area (1 hospital and 6 primary care centers). Inclusion criteria: patients ≥ 20 years old who initiated treatment with insulin or GLP-1 during 2010-2012, T2DM diagnosis at least one year before initiation of injectable treatment. Patients were followed for one year. Adherence and persistence during the follow up period were analyzed. Medication Possession Ratio (MPR) was used as a proxy of adherence. MPR is calculated as the percentage of days covered by the medication prescribed during the study period. Persistence rate is defined as percentage of patients having prescriptions of the ongoing therapy continuously renewed without a gap of more than 30 days. RESULTS: